LENZ Therapeutics (NASDAQ:LENZ) Price Target Lowered to $26.00 at Citigroup

LENZ Therapeutics (NASDAQ:LENZ) had its price target reduced by Citigroup from $52.00 to $26.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages also recently weighed in on LENZ. Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Bank of America reduced their price target on LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Finally, William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.60.

LENZ Therapeutics Stock Performance

LENZ stock opened at $8.94 on Thursday. The firm has a market cap of $280.27 million, a price-to-earnings ratio of -3.18 and a beta of 0.52. The firm has a 50-day simple moving average of $13.95 and a two-hundred day simple moving average of $24.30. LENZ Therapeutics has a one year low of $8.56 and a one year high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million. As a group, equities analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Trading of LENZ Therapeutics

Several large investors have recently bought and sold shares of the stock. Quarry LP purchased a new position in shares of LENZ Therapeutics in the third quarter worth $27,000. Bfsg LLC acquired a new stake in shares of LENZ Therapeutics during the third quarter worth $30,000. State of Wyoming purchased a new stake in shares of LENZ Therapeutics during the fourth quarter valued at $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of LENZ Therapeutics during the fourth quarter valued at $32,000. Finally, Osaic Holdings Inc. increased its position in shares of LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics News Summary

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Company highlighted a successful LNZ100 launch and positioned the program as a potential blockbuster opportunity — product momentum and commercial potential support longer‑term upside. LENZ Therapeutics Surpasses Expectations with LNZ100 Launch
• Positive Sentiment: Q4/2025 earnings call emphasized a strong cash position and operational updates that may de‑risk near‑term funding concerns. That balance‑sheet strength is supportive for execution and runway. LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Citigroup cut its price target substantially from $52 to $26 but kept a “Buy” rating — a meaningful reset in valuation expectations that still implies sizable upside versus current levels. Benzinga
• Neutral Sentiment: Bank of America trimmed its price target to $29 (from $35) while maintaining a “Buy” rating — another analyst recalibration that tempers near‑term price targets but signals continued conviction. LENZ Therapeutics Given New $29.00 Price Target at Bank of America
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS forecasts slightly (FY2028 to $0.62 from $0.65; FY2029 to $1.71 from $1.84) — the analyst kept a Buy rating but the cuts signal moderated profitability expectations out a few years. MarketBeat – HC Wainwright EPS Revisions
• Negative Sentiment: Recent reported Q4 results missed consensus: EPS and revenue were below estimates, and consensus for the current year remains negative — short‑term fundamentals and missed guidance/revenue contributed to the sell‑side caution. LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.